Allergic bronchopulmonary aspergillosis: Lessons for the busy radiologist

Ritesh Agarwal

The probability of a radiologist interpreting a disease correctly is not only influenced by their training and experience but also on the knowledge of a particular entity. This editorial reviews certain myths and realities associated with radiological manifestations of allergic bronchopulmonary aspergillosis (ABPA). ABPA is a hypersensitivity disorder against the antigens of Aspergillus fumigatus (A. fumigatus). Although commonly manifesting with central bronchiectasis (CB), the disorder can present without any abnormalities on high-resolution computed tomography (HRCT) of the chest, so-called serologic ABPA (ABPA-S). HRCT of the chest should not be used in screening or in the initial diagnostic work up of asthmatics, as asthma without ABPA can manifest with findings of CB. High-attenuation mucus (HAM) is the pathognomonic sign of ABPA and is very helpful in the diagnosis of ABPA complicating asthma and cystic fibrosis. Instead of classifying ABPA based on the presence and absence of CB into ABPA-CB and ABPA-S respectively, ABPA should be classified as ABPA-S, ABPA-CB and ABPA-CB-HAM. The classification scheme based on HAM not only identifies an immunologically severe disease but also predicts a patient with increased risk of recurrent relapses.
bronchi, and areas of atelectasis, whereas rare findings include pleural effusion, perihilar bronchocele mimicking adenopathy, miliary nodules, and unilateral lung collapse. Chest radiographic findings are non-specific and high-resolution computed tomography (HRCT) of the chest is the radiological investigation of choice in ABPA. The findings on HRCT chest include central bronchiectasis (CB, defined as bronchiectasis limited to the medial half of the lung, at a point midway between the hilum and the chest wall), mucus plugging with bronchocele formation and others (Table 3) [10]. Since its first description in 1952, numerous advances have taken place, and the remaining portion of the article will discuss the recent radiological advances associated with this condition.

ABPA CAN PRESENT WITH NORMAL HRCT CHEST

It is the usual belief of clinicians and radiologists that all patients with ABPA should manifest with CB on HRCT chest (Figure 1). However, ABPA is primarily a serological diagnosis and lung biopsy is rarely, if ever, needed in the diagnostic work up. Moreover, the earliest stage of ABPA is serologic ABPA (ABPA-S) in which the patients fulfill all other diagnostic criteria but do manifest with CT abnormalities [11]. In fact, in Chest or Asthma clinics where there is an active screening program in asthmatics for ABPA, almost 25% of ABPA will be diagnosed in the serological stage, even in developing countries [12].

ROLE OF CT IN THE DIAGNOSIS OF ABPA

While CB is believed to be a characteristic finding of ABPA, HRCT chest by itself has a poor specificity in distinguishing between various causes of bronchiectasis [13]. In fact, in one study the sensitivity of CB in the diagnosis of ABPA was only 37% [10]. Moreover, patients with ABPA can have central as well as peripheral bronchiectasis. In our study, we found that almost 40% of patients with ABPA have concomitant peripheral bronchiectasis [10]. To add to the confusion, patients with asthma can also develop bronchiectasis [14,15]. Although in asthmatic patients, bronchiectasis affecting three or more lobes, centrilobular nodules, and mucoid impaction on HRCT are believed to be suggestive of ABPA [16], a recent paper noted all these findings in patients with asthma with A. fumigatus sensitization without ABPA [18]. CT has also been proposed as a tool in the routine diagnostic work up of asthmatics with minimal diagnostic criteria (asthma, A. fumigatus skin test positivity and CB) used for the diagnosis of ABPA [19]. However, the occurrence of bronchiectasis in asthmatics without ABPA limits the utility of this approach. Rather, minimal diagnostic criteria for ABPA should include all of the following: asthma, A. fumigatus skin test positivity, raised serum total and A. fumigatus specific IgE levels.

### Table 1 Diagnostic criteria for allergic bronchopulmonary aspergillosis [3]

| Predisposing conditions | Obligatory criteria |
|-------------------------|---------------------|
| Bronchial asthma, cystic fibrosis, chronic obstructive lung disease | Elevated total IgE levels (> 1000 IU/mL) |
| Elevated IgG and/or IgE against A. fumigatus | Other criteria (at least three of five) |
| Immediate cutaneous hypersensitivity to A. fumigatus antigen (type 1 reaction) | Presence of serum precipitins against A. fumigatus |
| Fixed/transient pulmonary opacities on chest radiograph | Peripheral blood eosinophil count > 1000 cells/μL |
| Bronchiectasis on HRCT chest | Please retain HRCT chest |

A. fumigatus; Aspergillus fumigatus; HRCT: High-resolution computed tomography.

### Table 2 Chest radiographic findings encountered in patients with allergic bronchopulmonary aspergillosis

| Transient changes | Consolidation |
|-------------------|---------------|
| Mucoid impaction - “finger-in-glove” and toothpaste shadows | Atelectasis |
| Bronchial wall thickening - tramline shadows | Nodular opacities |
| Rare: Pleural effusion, air-fluid levels due to fluid filled bronchiectatic cavities, perihilar bronchocele simulating adenopathy, unilateral lung collapse, miliary nodules | Fixed changes |
| Bronchiectatic cavities | Rare: Pulmonary fibrosis and scars, pleural thickening, pneumothorax |

### Table 3 High-resolution computed tomography chest findings in allergic bronchopulmonary aspergillosis

| Central bronchiectasis, extensive and involving more than three lobes | Mucus plugging, usually hypodense |
| Mucus plugging with or without tree-in-bud opacities | High attenuation mucus, seen in up to 20% of patients |
| Centrilobular nodules | Atelectasis, generally subsegmental or segmental |
| Areas of consolidation | Mosaic attenuation due to air trapping |

HIGH-ATTENUATION MUCUS IS THE PATHOGNOMONIC SIGN OF ABPA

High-attenuation mucus (HAM) remains an important radiological sign in differentiating ABPA from asthma or other causes of bronchiectasis. The bronchial mucus plugging in ABPA is generally hypodense; however, mucus secretions can also have high attenuation CT values [10]. HAM is defined as the presence of mucus, which is denser than normal paraspinal skeletal muscle (Figure 2) [20-22]. Although present in only about 20% of ABPA complicating bronchial asthma [13], it is a characteristic finding and can be very useful in differential diagnosis. The presence of HAM in patients with bronchiectasis confirms ABPA...
The diagnosis of HAM is also very important in patients with CF. Unlike asthma, the diagnosis of ABPA complicating CF is difficult, as ABPA shares many clinical features with CF-related lung disease without ABPA. Wheezing, fleeting pulmonary infiltrates, bronchiectasis and mucus plugging are common manifestations of CF-related pulmonary disease with or without ABPA. The finding of HAM suggests that the lung disease is due to ABPA rather than CF per se.

**RADIOLOGICAL CLASSIFICATION OF ABPA SHOULD BE BASED ON HAM**

ABPA is radiologically classified as ABPA-CB or ABPA-S, respectively, depending on the presence or absence of bronchiectasis. It was hypothesized that ABPA-S represents the earliest stage of ABPA with less severe immunologic findings compared to ABPA-CB. However, in this study only the *A. fumigatus* specific IgG levels and precipitins were higher in patients with ABPA-CB, whereas the other immunologic parameters (total and *A. fumigatus* specific IgE values) were similar in the two groups. One author has also classified the disease into three groups: ABPA-S (mild), ABPA-CB (moderate) and ABPA-CB-other radiologic findings (ORF). However, this study included only 18 patients, and the HRCT findings in ORF included pulmonary fibrosis, bleb, bullae, pneumothorax, parenchymal scarring, emphysematous changes, multiple cysts, fibrocavitary lesions and pleural thickening, all findings representing the fibrotic, immunologically inactive disease. In the largest study published on ABPA to date, we not only assessed the immunological parameters in both the earlier classifications but also suggested a new classification scheme based on HAM. We propose that ABPA should be classified as ABPA-S, ABPA-CB and ABPA-CB-HAM. In a study involving 234 patients with ABPA, we found that the classification scheme of Patterson et al. and Greenberger et al. showed immunological severity only in some parameters (eosinophil count and *A. fumigatus* specific IgE levels) but not in others (total IgE levels). Moreover, on excluding patients with HAM, the immunological severity was restricted only to eosinophil counts. Interestingly, in the Kumar classification, the immunological markers were most severe in patients with ABPA-CB and not ABPA-CB-ORF. This suggests that ORF do not determine serological severity and probably represents the burnt out phase of the disease.

The presence of HAM at diagnosis not only represents immunologically severe disease but also identifies a patient who is at risk of recurrent relapses. In a multivariate analysis, both CB and HAM were independent predictors of frequent relapses of ABPA (OR 3.41; 95% CI: 1.45-8.01 and OR 3.61; 95% CI: 1.23-10.61, respectively).
CONCLUSION

All patients with bronchial asthma should be routinely screened with an *Aspergillus* skin test with the aim of diagnosing ABPA before the development of bronchiectasis. As bronchiectasis is a poor prognostic marker in the natural history of this disease, HRCT findings not only help in the diagnosis of ABPA but can also predict outcome. HAM is a pathognomonic sign of ABPA. ABPA should be classified based on HRCT findings as ABPA-S, ABPA-CB and ABPA-CB-HAM as the presence of HAM at diagnosis represents immunologically severe disease and identifies patients at risk for recurrent relapses.

REFERENCES

1. Agarwal R. Allergic bronchopulmonary aspergillosis. *Chest* 2006; 130: 805-826.
2. Agarwal R. Allergic Bronchopulmonary Aspergillosis. In: Jindal SK, Shankar PS, Raoof S, Gupta D, Aggarwal AN, Agarwal R, editors. Textbook of Pulmonary and Critical Care Medicine. 1st ed. New Delhi: Jaypee Publications, 2010: 947-970.
3. Agarwal R, Chakrabarti A. Clinical Manifestations and Natural History of Allergic Bronchopulmonary Aspergillosis. In: Pasqualotto AC, editor. Aspergillosis: From Diagnosis to Prevention. New York: Springer, 2009: 707-724.
4. Agarwal R. Controversies in allergic bronchopulmonary aspergillosis. *Int J Respir Care* 2010; 6: 53-54, 56-63.
5. Agarwal R, Hazarika B, Gupta D, Aggarwal AN, Chakrabarti A, Jindal SK. Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA? *Med Mycol* 2010; 48: 988-994.
6. Lynch DA. Imaging of asthma and allergic bronchopulmonary mycosis. *Radiol Clin North Am* 1998; 36: 129-142.
7. Agarwal R, Reddy C, Gupta D. An unusual cause of hilar lymphadenopathy. *Lung India* 2006; 23: 90-92.
8. Agarwal R, Aggarwal AN, Gupta D, Bal A, Das A. Case report: A rare cause of miliary nodules -- allergic bronchopulmonary aspergillosis. *Br J Radiol* 2009; 82: e151-e154.
9. Agarwal R, Aggarwal AN, Gupta N, Gupta D. A rare cause of acute respiratory failure - allergic bronchopulmonary aspergillosis. *Mycoses* 2011; 54: e223-e227.
10. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. *Chest* 2006; 130: 442-448.
11. Agarwal R, Khan A, Aggarwal AN, Saikia B, Gupta D, Chakrabarti A. Role of inhaled corticosteroids in the management of serological allergic bronchopulmonary aspergillosis (ABPA). *Intern Med* 2011; 50: 855-860.
12. Agarwal R, Khan A, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. *PLoS One* 2010; 5: e15346.
13. Lee PH, Carr DH, Rubens MB, Cole P, Hansell DM. Accuracy of CT in predicting the cause of bronchiectasis. *Clin Radiol* 1995; 50: 839-841.
14. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. *AJR Am J Roentgenol* 1995; 165: 261-267.
15. Needel DA, Goodman LR, Gurney JW, Greenberger PA, Fink JN. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. *Am Rev Respir Dis* 1990; 142: 1200-1205.
16. Paganin F, Trussard V, Seneterre E, Chanez P, Giron J, Godard P, Sénac JP, Michel FB, Bouquet J. Chest radiography and high resolution computed tomography of the lungs in asthma. *Am Rev Respir Dis* 1992; 146: 1084-1087.
17. Ward S, Heyneman L, Lee MJ, Leung AN, Hansell DM, Müller NL. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. *AJR Am J Roentgenol* 1999; 173: 937-942.
18. Menezies D, Holmes L, McCumsey G, Pris-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. *Allergy* 2011; 66: 679-685.
19. Eaton T, Garrett J, Milne D, Frankel A, Wells AU. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. *Chest* 2000; 118: 66-72.
20. Agarwal R, Aggarwal AN, Gupta D. High-attenuation mucus in allergic bronchopulmonary aspergillosis: another cause of diffuse high-attenuation pulmonary abnormality. *AJR Am J Roentgenol* 2006; 186: 904.
21. Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A, Jindal SK. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. *Chest* 2007; 132: 1183-1190.
22. Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Saikia B, Chakrabarti A, Jindal SK. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. *Respir Med* 2010; 104: 204-210.
23. Morozov A, Applegate KE, Brown S, Howenstine M. High-attenuation mucus plugs on MDCT in a child with cystic fibrosis: potential cause and differential diagnosis. *Pediatr Radiol* 2007; 37: 592-595.
24. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. *Arch Intern Med* 1986; 146: 916-918.
25. Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. *Ann Allergy* 1993; 70: 333-338.
26. Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. *Chest* 2003; 124: 890-892.

S-Editor Cheng JX L-Editor Webster JR E-Editor Zheng XM